CN107669993B - Anti-fatigue composition and application thereof - Google Patents
Anti-fatigue composition and application thereof Download PDFInfo
- Publication number
- CN107669993B CN107669993B CN201710616140.5A CN201710616140A CN107669993B CN 107669993 B CN107669993 B CN 107669993B CN 201710616140 A CN201710616140 A CN 201710616140A CN 107669993 B CN107669993 B CN 107669993B
- Authority
- CN
- China
- Prior art keywords
- parts
- fatigue
- prepared
- raw materials
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 239000007788 liquid Substances 0.000 claims abstract description 43
- 239000002994 raw material Substances 0.000 claims abstract description 24
- 241000893536 Epimedium Species 0.000 claims abstract description 22
- 235000018905 epimedium Nutrition 0.000 claims abstract description 22
- 244000237330 gutta percha tree Species 0.000 claims abstract description 17
- 241001264174 Cordyceps militaris Species 0.000 claims abstract description 16
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 16
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 15
- 241000258241 Mantis Species 0.000 claims abstract description 15
- 240000000249 Morus alba Species 0.000 claims abstract description 15
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 15
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 15
- 235000008397 ginger Nutrition 0.000 claims abstract description 15
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 14
- 235000011477 liquorice Nutrition 0.000 claims abstract description 14
- 230000036039 immunity Effects 0.000 claims abstract description 13
- 230000002708 enhancing effect Effects 0.000 claims abstract description 12
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 241000208688 Eucommia Species 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 244000241872 Lycium chinense Species 0.000 claims description 7
- 235000015468 Lycium chinense Nutrition 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 239000003760 tallow Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 3
- 241000283898 Ovis Species 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000002932 luster Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 38
- 210000004369 blood Anatomy 0.000 abstract description 37
- 230000036541 health Effects 0.000 abstract description 37
- 230000000694 effects Effects 0.000 abstract description 30
- 239000003814 drug Substances 0.000 abstract description 16
- 239000000463 material Substances 0.000 abstract description 16
- 235000013305 food Nutrition 0.000 abstract description 14
- 210000003734 kidney Anatomy 0.000 abstract description 13
- 235000017784 Mespilus germanica Nutrition 0.000 abstract description 7
- 244000182216 Mimusops elengi Species 0.000 abstract description 7
- 235000000560 Mimusops elengi Nutrition 0.000 abstract description 7
- 235000007837 Vangueria infausta Nutrition 0.000 abstract description 7
- 230000007774 longterm Effects 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000032683 aging Effects 0.000 abstract description 3
- 210000003127 knee Anatomy 0.000 abstract description 3
- 208000002193 Pain Diseases 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000003672 processing method Methods 0.000 abstract 1
- 230000008736 traumatic injury Effects 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 30
- 206010016256 fatigue Diseases 0.000 description 19
- 239000004310 lactic acid Substances 0.000 description 15
- 235000014655 lactic acid Nutrition 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 13
- 230000009182 swimming Effects 0.000 description 13
- 241000234314 Zingiber Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 229920002527 Glycogen Polymers 0.000 description 9
- 229940096919 glycogen Drugs 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000008961 swelling Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011775 sodium fluoride Substances 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010057040 Temperature intolerance Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- YXVFYQXJAXKLAK-UHFFFAOYSA-N biphenyl-4-ol Chemical group C1=CC(O)=CC=C1C1=CC=CC=C1 YXVFYQXJAXKLAK-UHFFFAOYSA-N 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 208000022119 inability to concentrate Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012716 precipitator Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000003997 social interaction Effects 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 241001480006 Clavicipitaceae Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 241001362421 Epimedium brevicornu Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000628927 Hierodula patellifera Species 0.000 description 1
- 206010020651 Hyperkinesia Diseases 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010051602 Laziness Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241001125875 Micropterus Species 0.000 description 1
- 241000218213 Morus <angiosperm> Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000228453 Pyrenophora Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 208000004209 confusion Diseases 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 206010013395 disorientation Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000009661 fatigue test Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- XMVONEAAOPAGAO-UHFFFAOYSA-N sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Insects & Arthropods (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to an anti-fatigue composition and application thereof, belonging to the technical field of health care products. The active ingredients of the composition are prepared from the following raw materials in parts by weight: 30-60 parts of mantis egg-case, 30-60 parts of medlar, 30-60 parts of epimedium herb, 80-120 parts of cordyceps militaris, 30-60 parts of eucommia ulmoides, 30-60 parts of liquorice, 50-70 parts of mulberry and 30-60 parts of ginger. The anti-fatigue composition adopts the traditional Chinese medicine processing method to prepare health care wine and health care oral liquid which can be used as health care food or medicine for tonifying kidney and replenishing vital essence, enhancing immunity, resisting fatigue, lowering blood pressure, lowering blood fat, resisting aging and resisting cancer for oral administration, and can also be used as health care food or medicine for traumatic injury and soreness and pain of waist and knees for external application. And the raw materials are food materials or medicinal and edible medicinal materials, accord with the theory of homology of medicine and food in traditional Chinese medicine, are natural, have low toxic and side effects, and are suitable for long-term administration.
Description
Technical Field
The invention relates to the technical field of health care products, in particular to an anti-fatigue composition and application thereof.
Background
Fatigue refers to the weakness of body function caused by hyperkinesia, lack of sleep, diseases and other reasons, and the subjective discomfort of tiredness, hypodynamia, muscle soreness, insomnia, palpitation and the like, and causes low immunity, easy cold, aging acceleration, and decline of working and learning abilities.
Modern medical research shows that the accumulation of energy substances, accumulation of 'fatigue toxin' fuscid, ammonia, urea, carbon dioxide and the like, free radical accumulation, immune function reduction or disorder and the like play an important role in the fatigue generation process. With the acceleration of the pace of life in modern society, especially fatigue states of white-collar men and women in offices are increasingly aggravated, the life pressure is large, the body is lack of exercise, and fatigue, weakness, muscle and joint soreness, dizziness, headache, palpitation, chest distress, sleep disorder, inappetence, abdominal discomfort, loose stool, constipation, sexual hypofunction, cold and heat intolerance, dry eyes and the like can be presented in the aspect of the body; the psychological aspect can be manifested by low mood, vexation, disorientation, dysphoria, irritability, fear, timidity, memory decline, inability to concentrate, energy deficiency, slow response, etc.; social interaction means that the body is in a state of fatigue for a long time, such as failure to properly play the corresponding social role, difficulty in working and learning, failure to properly deal with interpersonal and family relationships, and difficulty in normal social interaction.
At present, anti-fatigue products sold in domestic markets have various names, and can be roughly divided into two types of conventional functional beverages, the purposes of maintaining normal physiological functions of organisms and relieving fatigue are achieved by supplementing nutrients consumed in sports, such as red cattle, strength health care and the like, and the products have low content of general active ingredients, large dosage and poor timeliness; the other type is an anti-fatigue health-care product, the anti-fatigue effect of the product is generally not obvious from the prior anti-fatigue health-care food, the fundamental reason is that the formula is single, only the problem of a certain aspect of a human body is solved, and the human body is not taken as a system for comprehensive conditioning. The internal cause of fatigue is the pathogenesis of viscera deficiency, deficiency of qi and blood, yin and yang deficiency, and failure of long-term deficiency to recover into fatigue, and the five viscera deficiency syndrome is the main clinical manifestation of various chronic weakness syndromes. The five zang organs mainly store essence, and when the five zang organs have low function, essence cannot be stored, and the qi is damaged by labor and yin is damaged by overstrain, which results in deficiency of both qi and yin. Therefore, the existing product has a single formula, necessarily causes the anti-fatigue effect of the product to be smaller, and is suitable for narrower crowds.
Disclosure of Invention
In view of the above, there is a need to provide an anti-fatigue composition having immunity enhancing and anti-fatigue effects for a wide range of people.
The anti-fatigue composition comprises the following active ingredients in parts by weight:
30-60 parts of mantis egg-case, 30-60 parts of medlar, 30-60 parts of epimedium herb, 80-120 parts of cordyceps militaris, 30-60 parts of eucommia ulmoides, 30-60 parts of liquorice, 50-70 parts of mulberry and 30-60 parts of ginger.
The anti-fatigue composition takes the theory of traditional Chinese medicine as guidance, starts from the aspects of tonifying kidney and replenishing vital essence, nourishing yin and tonifying yang, is added or subtracted on the basis of the proved formula of doctors Liuming Han in the traditional Chinese medicine institute in the Jiannan province Yun county in the Hunan province recorded in the selection of longevity prescription, selects medicinal materials or food materials with dual purposes of medicine and food such as mantis egg-case, medlar, epimedium herb, cordyceps militaris, eucommia ulmoides, liquorice, mulberry, ginger and the like to be compatible and formulated, and is used for resisting fatigue. Wherein, the ootheca Mantidis tonifies kidney and supports yang, the Cordyceps militaris tonifies kidney essence and benefits primordial yang, the herba Epimedii tonifies kidney and benefits essence, the eucommia bark benefits essence and strengthens bones; medlar and mulberry are used for nourishing yin and enriching blood; the ginger is used for warming the middle-jiao and dispelling cold; the liquorice is used for tonifying middle-jiao and Qi and harmonizing the other drugs. The medicinal materials and the food materials are mutually matched and act synergistically to take effect together, so that the anti-fatigue effect is achieved.
The method comprises the following steps:
the ootheca Mantidis is dried ootheca of Mantis family insect, such as, the Mantis grandis Saussure, the Micropterus Statilimacula (Thurlberg) or the Mantis gigas Hierodula patellifera (Serpi 11 e). Has the effects of securing essence, reducing urination, tonifying kidney and supporting yang. It is commonly used for seminal emission, spermatorrhea, enuresis, frequent urination and whitish and turbid urine.
Lycium barbarum L.is mature fruit of Lycium barbarum L.of Solanaceae, and has effects of invigorating kidney, replenishing vital essence, nourishing liver, improving eyesight, replenishing blood, tranquilizing mind, promoting fluid production, quenching thirst, moistening lung, and relieving cough.
Cordyceps militaris L.Link, also called Cordyceps militaris, belongs to fungi of Ascomycotina, Pyrenophora, Escules, Clavicipitaceae, and Cordyceps. Has the functions of nourishing yin, moistening lung, invigorating kidney and strengthening yang, so that the product can be used as a tonic food for nourishing lung, invigorating kidney, stopping bleeding, eliminating phlegm, protecting lung, relieving dysentery, and relieving tuberculosis and cough.
Eucommia ulmoides Eucommiaulmoides Oliv is a famous and precious Chinese medicinal material, which is called as Shen nong's herbal medicine for treating pain in waist and knees, tonifying middle-jiao, replenishing vital essence, strengthening bones and muscles, removing yin, relieving itching and dampness and draining urine.
The herba Epimedii is dried leaf of Epimediumbrevicornu Maxim, Epimediumjiangye, SagittatumMaxim, Epimediumnakai, Pubescens Maxim, or Koreaanum nakai, and can be used for invigorating kidney, tonifying yang and dispelling pathogenic wind and dampness.
Mulberry is a general name of mature fruit clusters of Moraceae Morus plants, and has effects of regulating immunity, promoting hematopoietic cell growth, resisting mutagenesis, reducing blood sugar, reducing blood lipid, resisting aging, protecting liver, etc.
Glycyrrhiza glabra Glycyrrhiza GlandularissiFisch has the name: radix Angelicae Dahuricae, radix Glycyrrhizae, and radix Glycyrrhizae. Leguminosae, Glycyrrhiza, perennial herbs are commonly used for harmonizing the effects of the drugs in all directions.
The rhizoma Zingiberis recens is fresh rhizome of Zingiber officinale Roscoe of Zingiberaceae, and has pungent taste and mild nature. It enters lung, spleen and stomach meridians. Has effects in relieving exterior syndrome, dispelling cold, warming middle warmer, relieving vomit, warming lung, relieving cough, and removing toxic materials.
In one embodiment, the active ingredients of the composition are prepared from the following raw materials in parts by weight:
35-45 parts of salted mantis egg-case, 35-45 parts of Chinese wolfberry, 35-45 parts of moxibustion epimedium herb, 90-110 parts of cordyceps militaris, 35-45 parts of salted eucommia ulmoides, 45-55 parts of liquorice, 55-65 parts of mulberry and 35-45 parts of ginger.
In one embodiment, the salt ootheca mantidis is prepared by the following method: adding ootheca Mantidis into sodium chloride water solution, soaking, heating, and evaporating to dry;
the moxibustion epimedium is prepared by the following method: heating adeps Caprae Seu Ovis for melting, adding herba Epimedii, parching until the surface shows uniform oily luster and is yellow, and taking out;
the salt eucommia bark is prepared by the following method: adding sodium chloride aqueous solution into Eucommiae cortex, soaking, and heating to brown;
in one embodiment, in the preparation of the salt ootheca Mantidis, the usage ratio of the ootheca Mantidis and the sodium chloride is 1-4kg of sodium chloride per 100kg of the ootheca Mantidis;
in the preparation of the moxibustion epimedium herb, the using amount ratio of the epimedium herb to the mutton tallow oil is 15-25kg of mutton tallow oil per 100kg of epimedium herb;
in the preparation of the salt eucommia ulmoides, the usage amount ratio of the eucommia ulmoides to the sodium chloride is 1-3kg of the sodium chloride per 100kg of the eucommia ulmoides.
Through the processing, the properties of the traditional Chinese medicines can be better exerted and matched.
In one embodiment, the anti-fatigue composition is a wine, and is prepared by the following method: taking the raw materials, adding the edible wine according to the amount of 1000-.
In one embodiment, the anti-fatigue composition is a poultice, and is prepared by the following method: pulverizing the raw materials into powder, and blending with edible wine.
In one embodiment, the anti-fatigue composition is an oral liquid and is prepared by the following method: taking raw materials, adding water according to the amount of 5-10ml/g, decocting for 1-6 hours, and filtering to obtain filtrate;
or
The preparation method comprises the following steps: taking raw materials, respectively adding water according to the amount of 5-10ml/g, decocting for 1-6 hours, respectively preparing ootheca Mantidis extract, fructus Lycii extract, herba Epimedii extract, scarlet caterpiller fungus extract, eucommia bark extract, Glycyrrhrizae radix extract, Mori fructus extract, and rhizoma Zingiberis recens extract, and blending according to the raw material ratio to obtain the final product;
in one embodiment, the anti-fatigue composition is a granule, and is prepared by the following method: pulverizing the raw materials into superfine powder.
In one embodiment, a flavoring agent is added to the anti-fatigue composition to modify the taste.
Use of a composition as described above for the preparation of a formulation for enhancing immunity.
The use of the above composition in the preparation of a formulation for combating fatigue.
Compared with the prior art, the invention has the following beneficial effects:
the anti-fatigue composition disclosed by the invention is prepared from medicinal and edible medicinal materials or food materials such as mantis egg-case, Chinese wolfberry, epimedium herb, cordyceps militaris, eucommia ulmoides, licorice, mulberry, ginger and the like through compatibility and formula, and is used for resisting fatigue. Wherein, the ootheca Mantidis tonifies kidney and supports yang, the Cordyceps militaris tonifies kidney essence and benefits primordial yang, the herba Epimedii tonifies kidney and benefits essence, the eucommia bark benefits essence and strengthens bones; medlar and mulberry fruit are used for nourishing yin and enriching blood; the ginger is used for warming the middle-jiao and dispelling cold; the liquorice is used for tonifying middle-jiao and Qi and harmonizing various medicines. The medicinal materials and the food materials are matched with each other, have synergistic effect, and take effect together to achieve the effect of resisting fatigue, and can have the effect of resisting fatigue on a wide range of people. Experiments prove that the composition also has the effect of enhancing the immunity.
In addition, the raw materials are food materials or medicinal and edible medicinal materials, the theory of 'homology of medicine and food' in traditional Chinese medicine is met, the raw materials are reasonable in compatibility, natural and low in toxic and side effects, and the health-care food is suitable for long-term taking.
Detailed Description
In order that the invention may be more fully understood, reference will now be made to the following description. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.
The raw materials of the following examples were processed by the following methods:
salted mantis egg-case: cleaning clean ootheca Mantidis, removing impurities such as dust, pulverizing into coarse powder, adding saline water, stirring, moistening, placing in a pot, heating with slow fire, parching until fragrance is released, taking out, and cooling to obtain ootheca Mantidis salt, wherein 2.5kg of salt is used for each 100kg of ootheca Mantidis.
Roasting epimedium: cleaning herba Epimedii, removing impurities such as dust, shredding, removing pedicel and fine stalk, and sun drying. Heating adeps Caprae Seu Ovis oil for melting, adding herba Epimedii shreds, parching with slow fire until the surface shows uniform oily luster and slight yellow color, taking out, and cooling to obtain processed herba Epimedii. 20kg of refined mutton tallow oil is used for every 100kg of epimedium.
Salt eucommia bark: cleaning Eucommiae cortex, removing impurities such as dust, making into block or shred, adding saline water, stirring, moistening, parching with middle fire until the shred is broken, taking out when the surface is brown, spreading and drying in the air, and cooling thoroughly to obtain salted Eucommiae cortex, wherein the amount of salt is 2kg per 100kg Eucommiae cortex.
Example 1
An anti-fatigue composition is prepared into health care wine by the following method:
(1) 40g of salted mantis egg-case, 40g of Chinese wolfberry, 40g of moxibustion epimedium herb, 100g of cordyceps militaris, 40g of salted eucommia ulmoides, 50g of liquorice, 60g of mulberry and 40g of ginger.
(2) 1000mL of 56-degree white spirit brewed from commercial pure grains is added to the mixture, and the mixture is sealed and soaked in a cool and dry place for 15 days.
(3) Filtering the health wine soaked in the step (2) for 15 days, adding 1% of honey for blending, and encapsulating to obtain the health wine.
The health care wine prepared by the embodiment can be taken orally or applied externally for kneading, and the recommended amount of oral administration is 1-2 times per day, and each time is 20-30 mL; the health wine is applied and kneaded on the affected part for 4-6 times per day according to the area of the applied part, so that good anti-fatigue effect can be achieved.
Example 2
An anti-fatigue composition is prepared into a health-care oral liquid A and is prepared by the following preparation method:
(1) 40g of salted mantis egg-case, 40g of Chinese wolfberry, 40g of moxibustion epimedium herb, 100g of cordyceps militaris, 40g of salted eucommia ulmoides, 50g of liquorice, 60g of mulberry and 40g of ginger.
(2) Adding 5 times (1g of raw materials added with 5ml of water) of water according to the material-liquid ratio of 1:5, decocting twice with slow fire for 2 hours each time, combining the two decoctions, standing to room temperature, and filtering for later use.
(3) And (3) adding citric acid, honey, white granulated sugar and other flavoring agents into the filtered decoction in the step (2) to prepare the taste, standing, filtering, adding a potassium sorbate preservative into the supernatant according to the national standard, filling, sealing and sterilizing to obtain the beverage.
The anti-fatigue health-care oral liquid prepared by the embodiment is mainly suitable for teenagers and old people who are not suitable for drinking, and 30-50mL of the anti-fatigue health-care oral liquid is recommended to be drunk every day, so that good effects of enhancing immunity, resisting fatigue and the like can be achieved.
Example 3
An anti-fatigue composition is prepared into granules by the following method:
(1) taking 40g of salted ootheca Mantidis, 40g of medlar, 40g of moxibustion epimedium herb, 100g of cordyceps militaris, 40g of salted eucommia ulmoides, 50g of liquorice, 60g of mulberry and 40g of ginger.
(2) Micronizing to obtain micropowder (particle diameter less than 1 μm);
(3) the super micro powder 1g is independently packaged and can be drunk after being brewed by adding 400mL of hot water, and can also be brewed by mixing with the soymilk powder, so that the flavor, the taste and the health care effect are better.
Example 4
An anti-fatigue composition for health care application is prepared by the following method
(1) 40g of salted mantis egg-case, 40g of Chinese wolfberry, 40g of moxibustion epimedium herb, 100g of cordyceps militaris, 40g of salted eucommia ulmoides, 50g of liquorice, 60g of mulberry and 40g of ginger. Pulverizing into fine powder or superfine powder
(2) According to the area of the affected part, a proper amount of the fine powder or the superfine powder is mixed with a proper amount of yellow wine to form a paste, and the paste is uniformly applied to the affected part.
Comparative example 1
An anti-fatigue composition is prepared into a health-care oral liquid B, which is basically the same as the health-care oral liquid in example 2, except that the anti-fatigue composition is prepared from the following raw materials:
40g of medlar, 40g of moxibustion epimedium herb, 40g of salt eucommia bark, 50g of liquorice, 60g of mulberry and 40g of ginger.
Comparative example 2
An anti-fatigue composition is prepared into a health oral liquid C, which is basically the same as the health oral liquid in example 2, except that the anti-fatigue composition is prepared from the following raw materials:
40g of salted mantis egg-case, 40g of Chinese wolfberry, 100g of cordyceps militaris, 40g of salted eucommia ulmoides, 50g of liquorice and 40g of ginger.
Comparative example 3
An anti-fatigue composition, prepared as a health oral liquid D, was substantially the same as the health oral liquid of example 2, except that the following raw materials were selected for preparation:
40g of salted mantis egg-case, 40g of moxibustion epimedium herb, 100g of cordyceps militaris, 50g of liquorice and 60g of mulberry.
Experimental example 1 anti-fatigue health oral liquid immunity enhancement experiment
An experiment for enhancing immunity was performed using the anti-fatigue health oral liquids prepared in the above example 2 and comparative example.
First, experiment method
1. Experimental animals and groups: 18-22 g male mice were randomly grouped into 10 mice per group and grown for 1 week adaptively. The immunity enhancing effect of the anti-fatigue health oral liquid is judged by inhibiting delayed type allergic reaction and enhancing carbon clearance capacity.
2. The immunity enhancing experiment administration method and dosage are as follows: the experiment shows that the anti-fatigue health oral liquid A, B, C and the experiment group D have the dosage of (1g of raw medicinal materials/(kg. D)), and a blank control group (intragastric distilled water) is arranged for oral intragastric administration, the intragastric administration amount is 0.2 mL/(D), and the oral administration is continuously fed for 30D.
3. Inhibition of delayed allergy: after 30min of the last sample giving, 20 mu L of dimethylbenzene is coated on the two sides of the right ear of the mouse, the cervical vertebra of the mouse is removed after 30min of the sample giving, after the whole auricle of the two ears is cut off, a hole is punched on the same part of the two ears by a 6mm puncher to obtain the mass, the difference between the two masses is used as an index of the swelling degree, the swelling inhibition rate is used as an index of the anti-inflammatory intensity, and the swelling degree and the swelling inhibition rate are respectively calculated according to the following formulas.
Swelling degree of ear is the quality of sensitized ear-unsensitized ear
Percent swelling inhibition rate (swelling degree of control group-swelling degree of experimental group)/swelling degree of control group x 100%
4. A3-fold diluted India ink is injected from tail vein of 100mL/kg (by weight) of mice, immediately recorded, 20 mu L of blood is taken from eye orbits after 2min and 10min, immediately added into 2mL of 0.1% Na2CO3 solution, the optical density is measured at the wavelength of 600nm by a 722 ultraviolet-visible spectrophotometer, the Na2CO3 solution is used as blank control, the mice are sacrificed, the liver and spleen are taken, the blood stains are sucked and dried, the carbon clearance of the mice are respectively weighed, the carbon clearance index (K) and the phagocytic index (α) are respectively calculated according to the following formulas.
K＝(lgOD1—lgOD2)/(t2—t1)
In the formula: OD1Optical density 2min after ink injection; OD2Optical density 10min after ink injection; t1 is 2 min; t2 is 10 min.
Second, experimental results
Table 1: anti-fatigue health oral liquid for treating mouse ear swelling caused by xylene
Note: p <0.05, the difference was significant.
As shown in Table 1, each experimental group of the anti-fatigue health oral liquid has an inhibition effect on mouse ear swelling caused by xylene, and the group A of the oral liquid has the best inhibition effect.
Table 2: influence of fatigue-resistant health oral liquid on carbon clearing capacity of mice
Note: the difference was very significant with p < 0.01.
As shown in table 2, the clearance index and phagocytic index of each experimental group of the anti-fatigue health oral liquid are higher than those of the blank control group, and it can be determined that the anti-fatigue health oral liquid has the ability of enhancing carbon clearance of mice, and the clearance index and phagocytic index of the oral liquid group a reach very significant difference levels compared with the blank control group, which indicates that the raw material ratio of the oral liquid group a has synergistic effect.
In conclusion, the anti-fatigue health oral liquid has positive indexes of delayed allergy and carbon clearance when being fed to mice, so the anti-fatigue health oral liquid has the effect of enhancing the immunity.
Experimental example 2 anti-fatigue health oral liquid anti-fatigue experiment
The anti-fatigue health oral liquids prepared in the above example 2 and comparative example were subjected to an anti-fatigue test.
First, experiment method
1. Experimental animals and groups: 18-22 g adult mice, each male and female half, are randomly grouped into 10 mice each group, and grow adaptively for 1 week. The anti-fatigue effect of the anti-fatigue health oral liquid is judged by the weight-bearing swimming time, the content of the hepatic glycogen and the content of the blood lactic acid respectively.
2. The administration method and dosage for the anti-fatigue experiment: the experiment shows that the anti-fatigue health oral liquid A, B, C and the experiment group D have the dosage of (1g of raw medicinal materials/(kg. D)), and a blank control group (intragastric distilled water) is arranged for oral intragastric administration, the intragastric administration amount is 0.2 mL/(D), and the oral administration is continuously fed for 30D.
3. Weight-bearing swimming time experiment: 30min after the last administration of the test sample, 5% of the lead skin by mass was bound to the root of the mouse tail, and the mouse was placed in water at about 25 ℃ for swimming, and the time from swimming to death was recorded.
4. Liver glycogen content determination: 30min after the last sample giving, the mice are killed, the liver is taken and rinsed by normal saline, then water is sucked, 100mg is accurately weighed, 8mL of 5% trichloroacetic acid is added, homogenate is carried out for 1min, then homogenate is placed in a 10mL centrifuge tube, and centrifugation is carried out for 15min at 3000 r/min. And taking 1mL of supernatant into a 10mL centrifuge tube, adding 4mL of 95% ethanol, shaking until no interface exists between the two liquids, and standing at room temperature overnight to extract glycogen. After the precipitation is completed, centrifuging at 3000 r/min for 15min, discarding the supernatant, and dissolving glycogen with 2mL of distilled water. Taking 2mL of distilled water as a blank, uniformly mixing 0.5mL of 1mg/mL glucose standard solution and 1.5mL of distilled water to be used as a standard tube, measuring absorbance at the wavelength of 620nm by an anthrone method, and calculating the glycogen content according to the following formula:
hepatic glycogen content/(mg/100 g) ═ AS/A0×0.5×VExtract liquid/mLiver tissue×100×0.9
In the formula: a. thesIs the sample tube absorbance; a. the0Is the standard tube absorbance; 0.5 is 0.5mg, i.e. the glucose content in 0.5mL glucose standard solution; vExtract liquid8 mL; m isLiver tissue0.1 g; 100 is 100g of liver tissue; 0.9 is a conversion coefficient for converting glucose into glycogen.
5. And (3) blood lactic acid content determination: collecting blood 30min after the last sample application, immediately collecting blood after swimming in water with water temperature of about 30 deg.C for 10min under the condition of no load, and collecting blood 3 rd after resting for 20 min. Accurately sucking 20 mu L of whole blood, adding the whole blood into the bottom of a 5mL test tube filled with 0.48mL of 1% sodium fluoride solution in advance, adding 1.5mL of protein precipitator (prepared by mixing 10% sodium tungstate, 0.33mol/L sulfuric acid and distilled water according to the volume ratio of 1: 28), fully oscillating and uniformly mixing, centrifuging at 3000 r/min for 10min, taking supernate, and measuring the blood lactic acid content, wherein the operation is as follows:
respectively setting a measuring tube, a standard tube and a blank tube; adding 0.5mL of supernatant into a measuring tube, and respectively adding the same volume of lactic acid standard solution and precipitator-sodium fluoride mixed solution (formed by mixing a protein precipitator and a sodium fluoride solution according to the volume ratio of 3: 1) into a standard tube and a blank tube; then respectively adding 0.1mL of 4% copper sulfate solution and 3mL of concentrated sulfuric acid into each tube; mixing the tubes, and boiling in water bath for 5 min; taking out, and cooling in ice water bath for 10 min; then 0.1mL of 1.5% p-hydroxybiphenyl is added into each tube, and the volume is 0.1 mL; shaking, and placing in 30 deg.C water bath for 30min, shaking 1 time every 10 min. Taking out, boiling in water bath for 90s, taking out, cooling to room temperature, measuring absorbance at wavelength of 560nm, and zeroing the blank tube. The blood lactate content, the area under the blood lactate curve and the blood lactate recovery rate were calculated as follows.
Blood lactic acid content/(mg/L) ═ AMeasuring tube/AStandard tube×100×10
Area under the blood lactic acid curve 5 × (blood lactic acid value before swimming +3 × blood lactic acid value after swimming + 0min blood lactic acid value after swimming + 2 × blood lactic acid value after resting for 20min after swimming)
Rate of recovery from blood lactic acid/(mg/(L · min)) ═ (blood lactic acid value 0min after swimming-blood lactic acid value 20min after swimming)/(20 min-0 min)
Second, experimental results
Table 3: effect of antifatigue health oral liquid on mouse antifatigue I
Table 4: effect of antifatigue health oral liquid on mouse antifatigue II
Note: p <0.05, significant difference; the difference was very significant with p < 0.01.
As shown in tables 3-4, the swimming time of each experimental group of the anti-fatigue health-care oral liquid is longer than that of the blank control group, the liver glycogen content is also obviously higher than that of the blank control group, the area under the blood lactic acid curve is smaller than that of the blank control group, and the recovery rate is higher than that of the control group, so that the weight-bearing swimming time of a mouse taking the anti-fatigue health-care oral liquid for a long time is obviously prolonged, the liver glycogen content is obviously increased, and the blood lactic acid content is obviously reduced after swimming, so that the anti-fatigue health-care oral liquid has the function of relieving physical fatigue. However, compared with the blank control group, the oral liquid A group has very obvious difference (P is less than 0.05) and has the best anti-fatigue effect.
Experimental example 3 summary of clinical effects of anti-fatigue health oral liquid
Firstly, selecting an object:
500 patients are selected, 125 patients are above 45 years old, the male-female ratio is 1.2:1, 200 patients are 20-45 years old, the male-female ratio is 1.5:1, 175 patients are 10-20 years old, and the male-female ratio is 1: 1. All diagnoses were: traditional Chinese medicine: fatigue due to kidney injury, manifested as: laziness in limbs, tinnitus, muddlehead, hypomnesis, soreness and weakness of waist and knees, and soreness and pain in heels. Pale tongue with thin and little coating or red tongue without coating, thready, rapid or soft-superficial and thready pulse; the western medicine diagnoses chronic fatigue syndrome, which is represented as: long-term (more than 6 consecutive months) unknown strength fatigue feeling or body discomfort fever, sore throat, swollen lymph nodes, loss of appetite, small intestine discomfort, jaundice, emotional lability, inability to concentrate attention, headache, etc.
Secondly, the treatment method comprises the following steps:
the anti-fatigue oral liquid A prepared by the method in the example 2 is taken by a patient every day, 20ml each time in the morning and evening, the oral liquid is taken after meals, other health care products and medicines are stopped taking during observation, and blood norms and blood biochemical indexes are detected after three weeks.
Thirdly, judging the curative effect:
(1) and (3) healing: clinical symptoms disappear or are normal, and the blood is normal, and the blood biochemical indexes (including white blood cell count (WBC), red blood cell count (RBC), platelet count (PLT), lymphocyte count (LY), ALT (alanine aminotransferase), AST (aspartate aminotransferase), ALB (albumin), A/G (serum/globulin), IgA (immunoglobulin), IgG (immunoglobulin), IgM (immunoglobulin), C.C.R (creatinine clearance rate) and the like) are all normal;
(2) the effect is shown: the clinical symptoms are obviously improved or close to normal, the blood is conventional and biochemical, most of the symptoms indicate that the symptoms are obviously improved or tend to normal;
(3) effective, the clinical symptoms are partially improved, and the individual indexes of the routine blood and the biochemistry of the blood are obviously improved or tend to be normal.
The observations are given in the following table:
to sum up: the anti-fatigue composition can obviously have an obvious anti-fatigue effect, is wide in applicable population, effective in a short time, low in toxic and side effects and suitable for long-term drinking.
The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (8)
1. The anti-fatigue composition is characterized in that the effective components of the composition are prepared from the following raw materials in parts by weight:
35-45 parts of salted mantis egg-case, 35-45 parts of Chinese wolfberry, 35-45 parts of roasted epimedium herb, 90-110 parts of cordyceps militaris, 35-45 parts of salted eucommia bark, 45-55 parts of liquorice, 55-65 parts of mulberry and 35-45 parts of ginger;
the salt ootheca Mantidis is prepared by the following method: adding ootheca Mantidis into sodium chloride water solution, soaking, heating, and evaporating to dry;
the roasted epimedium is prepared by the following method: heating adeps Caprae Seu Ovis for melting, adding herba Epimedii, parching until the surface shows uniform oily luster and is yellow, and taking out;
the salt eucommia bark is prepared by the following method: adding sodium chloride aqueous solution into Eucommiae cortex, soaking, and heating to brown.
2. The anti-fatigue composition according to claim 1, wherein the salt ootheca Mantidis is prepared by using 1-4kg of sodium chloride per 100kg of ootheca Mantidis;
in the preparation of the fried epimedium, the using amount ratio of the epimedium to the mutton tallow oil is 15-25kg of mutton tallow oil per 100kg of epimedium;
in the preparation of the salt eucommia ulmoides, the usage amount ratio of the eucommia ulmoides to the sodium chloride is 1-3kg of the sodium chloride per 100kg of the eucommia ulmoides.
3. The anti-fatigue composition according to any one of claims 1 to 2, wherein the anti-fatigue composition is a wine, and is prepared by the following method: taking the raw materials, adding the edible wine according to the amount of 1000-.
4. The anti-fatigue composition according to any one of claims 1-2, wherein the anti-fatigue composition is a poultice, and is prepared by the following method: pulverizing the raw materials into powder, and blending with edible wine.
5. The anti-fatigue composition according to any one of claims 1 to 2, wherein the anti-fatigue composition is an oral liquid and is prepared by the following method: taking raw materials, adding water according to the amount of 5-10ml/g, decocting for 1-6 hours, and filtering to obtain filtrate;
or
The preparation method comprises the following steps: taking the raw materials, respectively adding water according to the amount of 5-10ml/g, decocting for 1-6 hours, respectively preparing ootheca Mantidis extract, fructus Lycii extract, herba Epimedii extract, scarlet caterpiller fungus extract, Eucommiae cortex extract, Glycyrrhrizae radix extract, Mori fructus extract, and rhizoma Zingiberis recens extract, and blending according to the raw material ratio.
6. The anti-fatigue composition according to any one of claims 1-2, wherein the anti-fatigue composition is a granule prepared by the following method: pulverizing the raw materials into superfine powder.
7. Use of a composition according to any one of claims 1 to 6 in the manufacture of a formulation for enhancing immunity.
8. Use of a composition according to any one of claims 1 to 6 in the manufacture of a formulation for combating fatigue.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710616140.5A CN107669993B (en) | 2017-07-26 | 2017-07-26 | Anti-fatigue composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710616140.5A CN107669993B (en) | 2017-07-26 | 2017-07-26 | Anti-fatigue composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107669993A CN107669993A (en) | 2018-02-09 |
| CN107669993B true CN107669993B (en) | 2020-05-12 |
Family
ID=61133596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710616140.5A Active CN107669993B (en) | 2017-07-26 | 2017-07-26 | Anti-fatigue composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107669993B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631506A (en) * | 2012-04-24 | 2012-08-15 | 杨翠红 | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue |
| CN104893930A (en) * | 2015-06-30 | 2015-09-09 | 青岛浩大海洋保健食品有限公司 | Bushen Zhuangyang Baoshen compound wine |
| CN106334090A (en) * | 2016-11-10 | 2017-01-18 | 西藏城宇生物科技有限公司 | Traditional Chinese medicine composition for anti-fatigue and nourishing yin and tonifying yang and preparing method thereof |
-
2017
- 2017-07-26 CN CN201710616140.5A patent/CN107669993B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631506A (en) * | 2012-04-24 | 2012-08-15 | 杨翠红 | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue |
| CN104893930A (en) * | 2015-06-30 | 2015-09-09 | 青岛浩大海洋保健食品有限公司 | Bushen Zhuangyang Baoshen compound wine |
| CN106334090A (en) * | 2016-11-10 | 2017-01-18 | 西藏城宇生物科技有限公司 | Traditional Chinese medicine composition for anti-fatigue and nourishing yin and tonifying yang and preparing method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107669993A (en) | 2018-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103417837B (en) | Medlar health preserving cream of a kind of medicine-food two-purpose and preparation method thereof | |
| KR20110073717A (en) | A functional food and making method of thereof | |
| CN105265672B (en) | Production method of walnut diaphragma juglandis tea | |
| Reid | A Handbook of Chinese Healing Herbs: An Easy-to-Use Guide to 108 Chinese Medicinal Herbs and Dozens of Prepared Herba l Formulas | |
| CN104069474A (en) | Traditional Chinese medicine composition for treating seborrheic alopecia and preparation method thereof | |
| CN114748603B (en) | Pharmaceutical composition for preventing and treating new coronavirus pneumonia from changing or restoring yang and application thereof | |
| KR100773889B1 (en) | Composition containing effective ingredient of liquefied medical herb extracts for hangover removal and manufacturing method of thereof | |
| CN105056103A (en) | Steamed buns with assistant effect of reducing blood fat and cholesterol and processing method of steamed buns | |
| CN107669993B (en) | Anti-fatigue composition and application thereof | |
| CN113974162A (en) | Chinese pear syrup cubilose and preparation method thereof | |
| CN106421519A (en) | Health-care medical liquor | |
| CN106615512A (en) | Eggplant and honey throat-soothing candies and preparation method thereof | |
| CN106177651A (en) | A kind of infantile malnutrition medicine | |
| CN105343866A (en) | Traditional Chinese medicine tablets for treating cold rheum coughs and preparation method | |
| CN101342331A (en) | Traditional Chinese medicine for treating pulmonitis and upper respiratory tract infection | |
| CN104997956A (en) | Behcet's syndrome and treatment drug thereof | |
| CN105012743A (en) | Health maintaining congee with antihypertensive effect | |
| CN106360467A (en) | Red jujube and Chinese wolfberry fruit cakes | |
| CN105567530A (en) | Vinegar beverage having blood vessel softening effect and preparation method thereof | |
| CN105494768A (en) | Lung moistening and phlegm eliminating healthcare tea and preparation method thereof | |
| CN105056071A (en) | Traditional Chinese medicine prescription for prevention and treatment of arrhythmia and preparation method thereof | |
| CN104824222A (en) | Health-preserving traditional Chinese medicine tea beverage with mulberry leaves, white chrysanthemums and lophatherum gracile and preparation method | |
| CN105031389A (en) | Traditional Chinese medicine tablet for restraining malignant tumor breeding in cooperation with radiotherapy and preparing method of traditional Chinese medicine tablet | |
| CN104740478A (en) | Traditional Chinese medicine pill for emergency treatment of alcoholism and preparation method thereof | |
| CN116549589A (en) | Medicinal and edible composition for relieving cough and asthma, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| OL01 | Intention to license declared | ||
| OL01 | Intention to license declared | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240513 Address after: Room 802, Building C, Qingwang Science and Technology Park, Baohe Economic Development Zone, Hefei City, Anhui Province, 230041 Patentee after: Hefei xingzhicheng Information Technology Co.,Ltd. Country or region after: China Address before: 132000 no.3999 Binjiang East Road, Jilin City, Jilin Province Patentee before: BEIHUA University Country or region before: China |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240527 Address after: Room 701, Unit 1, C3 Building, No. 55 Hengbin Road, Jingxiu District, Baoding City, Hebei Province, 071051 Patentee after: Ren Yanfen Country or region after: China Address before: Room 802, Building C, Qingwang Science and Technology Park, Baohe Economic Development Zone, Hefei City, Anhui Province, 230041 Patentee before: Hefei xingzhicheng Information Technology Co.,Ltd. Country or region before: China |